Menu Search
Equities

Genedrive PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
D6M:STU

Genedrive PLC

Actions
  • Price (EUR)0.013
  • Today's Change0.013 / 2,500.00%
  • Shares traded0.00
  • 1 Year change-36.59%
  • Beta3.8347
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.

  • Revenue in GBP (TTM)954.00k
  • Net income in GBP-5.23m
  • Incorporated2007
  • Employees43.00
  • Location
    Genedrive PLC48 Grafton StreetMANCHESTER M13 9XXUnited KingdomGBR
  • Phone+44 161 989 0245
  • Fax+44 161 989 0262
  • Websitehttps://www.genedriveplc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.